Rapid Influenza Diagnostic Test Market

Rapid Influenza Diagnostic Test Market Outlook (2024 to 2034)

The global rapid influenza diagnostic test market size is expected to reach a valuation of US$ 1.13 billion in 2024 and expand at a CAGR of 8.7% to be worth US$ 2.61 billion by the end of 2034.

Influenza is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and also the lungs. This disease can cause mild to severe illness and can lead to death if not treated properly. Most people contract influenza when they breathe in tiny airborne droplets from the coughs or sneezes of someone who has the condition.

One can also contract this flu by touching surfaces contaminated with the virus and then touching their mouth, nose, or eyes. Given the global impact of the COVID-19 pandemic, individuals have become increasingly conscious of their health and are actively monitoring symptoms that could indicate such illnesses. This heightened awareness has driven up the demand for rapid influenza diagnostic test kits, thereby driving market growth.

Key Market Growth Drivers

• The market is benefitting from the increasing awareness of early diagnosis of flu symptoms in the wake of the COVID-19 pandemic. This is contributing to the expansion of the rapid influenza diagnostic test market size.
• Those aged 65 years and older are significantly more affected by this virus. Manufacturers of diagnostic test kits are targeting this demographic and actively analyzing the needs of older individuals to boost their sales.
• Suppliers are aware of the ever-evolving healthcare needs, and this understanding has prompted them to incorporate a range of features into their kits, which is projected to result in a significant increase in sales of rapid influenza diagnostic test kits.
• With a substantial elderly population, China is projected to lead the market in the East Asia region. The market in China is projected to expand at a CAGR of 8.4% from 2024 to 2024, thereby contributing significantly to the rapid influenza diagnostic test market share.
• Sales of rapid influenza test kits are projected to surge during select seasons, including rainy and cold periods, as health issues usually rise during these times.
• Manufacturers in the market are investing in enhancing the design, durability, and quality of these kits with the aim of prolonging their lifespan and enhancing their popularity among consumers.

Report Attributes	Details
Rapid Influenza Diagnostic Test Market Size (2024E)	US$ 1.13 Billion
Forecasted Market Value (2034F)	US$ 2.61 Billion
Global Market Growth Rate (2024 to 2034)	8.7% CAGR
Canada Market Growth Rate (2024 to 2034)	8.9% CAGR
China Market Value (2034F)	US$ 202 Million
North America Market Share (2024E)	38.3%
East Asia Market Share (2034F)	16.4%
Key Companies Profiled	Becton Abbott Laboratories Quidel Corporation Hologic Thermo Fisher Scientific Dickinson and Company Meridian Bioscience Inc. DiaSorin SpA

Which Rapid Influenza Diagnostics Test Kit Market Trends are Significant?

“Increasing Population with Compromised Immune Systems and Related Illnesses”

Demand for rapid influenza diagnostic tests is growing due to an increasing population with compromised immune systems and related illnesses. Human influenza viruses, including type A and B, contribute significantly to the burden of this illness. This raises healthcare expenses and affects quality of life.

• According to the World Health Organization (WHO), seasonal influenza causes approximately 3 to 5 million severe illnesses globally each year.
• The European Centre for Disease Prevention and Control reports that influenza affects 10% to 30% of Europe's population annually. Research findings from October 2020 to July 2021 indicate around 1.3 million cases.

These factors have fueled the adoption of influenza tests among the public, with a large number of individuals purchasing test kits in advance to ensure preparedness during emergencies. The market is projected to continue growing in the future, driven by increasing health concerns, particularly following the COVID-19 pandemic.

“Emphasis on Developing Faster and More Precise Diagnostic Technologies”

Increasing frequency of influenza throughout the world has boosted R&D efforts for improved detection and diagnosis. The majority of research work is focused on creating quicker and more accurate diagnostic technologies for influenza viruses, which is driving market expansion.

• The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), established the Collaborative Influenza Vaccine Innovation Centers (CIVICs) initiative to support a wide range of influenza research efforts. CIVICs is set to receive US$ 51 million in support from the NIAID.

“Advancements in Genomic Technology Facilitating Enhanced Surveillance Capabilities”

The Human Genome Project and breakthroughs in molecular and biomedical technology have generated massive amounts of data, resulting in the creation of several tests and technologies useful for the detection and treatment of influenza infections. These new technologies, which rely on genomic procedures (such as PCR) and proteomics (such as microarray-based detection), aid in the discovery of novel influenza viruses. They also enable better surveillance and quicker detection of infectious illnesses, creating commercial opportunities.

What are the Restraints Hindering Rapid Influenza Diagnostic Test Market Growth?

“Stringent Regulatory Framework Restricting Commercialization of Tests”

Most diagnostic businesses encounter significant challenges in commercializing their tests, including convincing Medicare and private health insurers to pay for them. This is crucial not just for clinicians' decision-making in the practice of evidence-based medicine, but also for obtaining regulatory permission and reimbursement for the tests. In recent years, regulatory approvals for influenza tests have become more demanding, ensuring their effectiveness in identifying all forms of influenza viruses.

“Seasonal Nature of Influenza Leading to Fluctuations in Demand for Diagnostic Testing”

One of the major impediments to market expansion is the seasonal nature of influenza. This causes oscillations in the need for diagnostic testing. Furthermore, demand for influenza diagnostics increases during flu seasons and decreases during off-peak periods. This uncertainty has a long-term negative impact on the influenza diagnostic industry. Disparities in healthcare infrastructure, particularly in underdeveloped and developing countries, also impede the general use of modern diagnostic tools. All of these problems limit the market's expansion.

Country-wise Evaluation

The South Korean market is projected to expand at a CAGR of 10.6% from 2024 to 2034. This is attracting test kit suppliers to the East Asia region.

Which Elements in the United States Market are Conducive for Market Growth?

“Robust Healthcare Infrastructure and Enhanced Capabilities in Pharmaceutical Research”

Attribute	United States
Market Value (2024E)	US$ 350 Million
Growth Rate (2024 to 2034)	8.8% CAGR
Projected Value (2034F)	US$ 814 Million

The United States has one of the most comprehensive and complex healthcare ecosystems in the world, complete with cutting-edge medical institutions, labs, and diagnostic centers. This promotes the wider use of novel influenza diagnostic technology, hence accelerating market growth. Aside from that, the country is a center for research and development in the healthcare and pharmaceutical industries. As a result, the United States has emerged as one of the world's major influenza diagnostic markets.

What Makes Japan a Profitable Market for Rapid Influenza Diagnostic Testing Providers?

“Government Investments in Enhancement of Diagnostic Laboratories”

Attribute	Japan
Market Value (2024E)	US$ 67 Million
Growth Rate (2024 to 2034)	9.8% CAGR
Projected Value (2034F)	US$ 171 Million

Japan's enhanced healthcare facilities have created a favorable environment for the growth of the market. The Japanese government's strong commitment to healthcare has led to significant investments in influenza diagnostic laboratories, testing camps, and temporary testing facilities, thereby boosting demand for influenza diagnostics.

Category-wise Insights

Among the end users, the retail pharmacy segment is forecasted to expand at a CAGR of 10% from 2024 to 2034. Market players are collaborating with retail pharmacies to enhance their presence.

Why is Inclusion of Nucleic Acid in Diagnostic Testing Kits Increasing Significantly?

“Molecular Fingerprints of Nucleic Acid Facilitating Identification of Various Viruses”

Attribute	Nucleic Acid
Segment Value (2024E)	US$ 320.2 Million
Growth Rate (2024 to 2034)	10.9% CAGR
Projected Value (2034F)	US$ 897.2 million

Inclusion of nucleic acid in diagnostic test kits is due to its molecular fingerprints, which facilitate the identification of various viral pathogens. This has established nucleic acid as a crucial component for ensuring the effectiveness and efficiency of diagnostic kits. Suppliers are actively seeking cost-effective sources of nucleic acid to enhance the affordability of these kits. The presence of nucleic acid significantly simplifies the detection of diseases like influenza, aiding in the prevention of such harmful chronic illnesses.

Which Sample Type is Widely Preferred for Accurate Testing Outcomes?

“Ease of Use Associated with Nasopharyngeal Swab Driving Preference”

Attribute	Nasopharyngeal Swab
Segment Value (2024E)	US$ 343.3 Million
Growth Rate (2024 to 2034)	9.1% CAGR
Projected Value (2034F)	US$ 820.9 Million

The nasopharyngeal airway is a thin, clear, and flexible tube that is inserted into a patient's nostril. The purpose of NPA is to bypass upper airway obstruction at the level of the nose, nasopharynx, or base of the tongue. It also helps prevent the tongue from falling backward on the pharyngeal wall to prevent obstruction. This sample test is user-friendly and straightforward, making it convenient for people to use and get checked quickly.

Business Competition

Key players in the rapid influenza diagnostic test market include Becton, Abbott Laboratories, F. Hoffmann-La Roche AG, Quidel Corporation, Hologic, and Thermo Fisher Scientific, among others. These key stakeholders collaborate to develop a wide array of advanced influenza diagnostic treatments and solutions. They provide influenza diagnostic solutions and technology to various entities such as hospitals, diagnostic laboratories, research and academic institutions, and contract research organizations.

While smaller firms also operate in the market, they typically have a smaller consumer base and marketing capacity. These companies often rely on the innovations of industry giants to incorporate new technology into their products.

• In November 2023, Mylab and Ekincare collaborated to promote NASOVAC-S4, an influenza nasal vaccine. Administered non-invasively and painlessly via the nasal route, it offers an attractive option for corporate employee wellness initiatives.
• In January 2023, Roche announced that the European Commission approved Xofluza for the treatment and prevention of influenza in children aged one year and older. This is the first influenza antiviral with a novel mode of action in almost 20 years, inhibiting virus multiplication quicker than oseltamivir.

Key Segments of Rapid Influenza Diagnostic Test Market Research

• By Principle :

  • Immunochromatographic Assays
  • Immunofluorescence Assays
  • Nucleic Acid Amplification Test

• By Test Type :

  • Influenza A Test
  • Influenza B Test
  • Influenza A+B Test

• By Sample Type :

  • Throat Swab
  • Nasal Swab
  • Nasal Aspirate
  • Nasal Wash
  • Nasopharyngeal Swab
  • Nasopharyngeal Aspirate
  • Nasopharyngeal Wash

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa